Immunomodulatory biomaterials : (Record no. 82600)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11742cam a2200601 a 4500 |
| 001 - CONTROL NUMBER | |
| control field | on1262436235 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20230516165942.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr |n||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210801s2021 enk o 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | YDX |
| Language of cataloging | eng |
| Description conventions | pn |
| Transcribing agency | YDX |
| Modifying agency | OPELS |
| -- | OCLCO |
| -- | UKMGB |
| -- | OCLCF |
| -- | N$T |
| -- | UKAHL |
| -- | UIU |
| -- | OCLCO |
| -- | OCLCQ |
| -- | K6U |
| -- | SFB |
| -- | OCLCQ |
| 015 ## - NATIONAL BIBLIOGRAPHY NUMBER | |
| National bibliography number | GBC195950 |
| Source | bnb |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER | |
| Record control number | 020226162 |
| Source | Uk |
| 019 ## - | |
| -- | 1287271319 |
| -- | 1287877424 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780128214565 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 0128214562 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780128214404 |
| Qualifying information | (paperback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 0128214406 |
| Qualifying information | (paperback) |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1262436235 |
| Canceled/invalid control number | (OCoLC)1287271319 |
| -- | (OCoLC)1287877424 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | R857.M3 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610.284 |
| Edition number | 23 |
| 245 00 - TITLE STATEMENT | |
| Title | Immunomodulatory biomaterials : |
| Remainder of title | regulating the immune response with biomaterials to affect clinical outcome / |
| Statement of responsibility, etc. | edited by Stephen F. Badylak, Jennifer Elisseeff. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Duxford : |
| Name of publisher, distributor, etc. | Woodhead Publishing, |
| Date of publication, distribution, etc. | 2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Woodhead Publishing series in biomaterials |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Print version record. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Immunomodulatory Biomaterials: Regulating the Immune Response with Biomaterials to Affect Clinical Outcome -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Engineering physical biomaterial properties to manipulate macrophage phenotype: From bench to bedside -- 1.1. Introduction -- 1.2. Role of macrophages in tissue repair and the foreign body response -- 1.3. Modulation of macrophage function via physical biomaterial properties in vitro -- 1.3.1. Stiffness -- 1.3.2. Topography or 3D architecture -- 1.3.3. Ligand presentation or geometry of adhesion -- 1.4. Macrophage response to implanted biomaterials in vivo -- 1.4.1. Non-degradable biomaterials -- 1.4.2. Degradable biomaterials -- 1.5. Clinical insight into the effect of physical biomaterial properties on macrophages during tissue repair -- 1.5.1. Dental implants -- 1.5.2. Wound dressings -- 1.5.3. Materials for cardiovascular repair -- 1.6. Conclusions and future directions -- References -- Chapter 2: Early factors in the immune response to biomaterials -- 2.1. Introduction -- 2.2. Protein adsorption -- 2.2.1. Complement cascade -- 2.2.2. Coagulation -- 2.2.3. Immunoglobulins -- 2.2.4. Innate immunity -- 2.2.4.1. Neutrophils -- 2.2.4.2. Mast cells -- 2.2.4.3. Macrophages/monocytes -- 2.2.5. Adaptive immunity -- 2.2.5.1. Dendritic cells -- 2.2.5.2. T Cells -- 2.2.5.3. B Cells -- 2.3. Foreign body giant cells -- 2.4. Fibrous capsule -- 2.5. Signaling pathways activated -- 2.5.1. TLRs and MyD88-dependent signaling -- 2.5.2. Inflammasome activation -- 2.5.3. JAK/STAT pathway -- 2.6. Conclusion -- References -- Chapter 3: Nanotechnology and biomaterials for immune modulation and monitoring -- 3.1. Introduction -- 3.2. Autoimmunity -- 3.3. Allergy -- 3.4. Transplant rejection -- 3.5. Clinical trials of tolerogenic nanotherapies -- 3.5.1. Liposomal. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.5.2. Virus-like particles -- 3.5.3. Metallic -- 3.5.4. Polymeric -- 3.6. Precision diagnostics -- 3.6.1. Liquid biopsy -- 3.6.2. Immunological niches -- 3.7. Outlook and conclusion -- Acknowledgments -- References -- Chapter 4: Immune-instructive materials and surfaces for medical applications -- 4.1. Introduction -- 4.1.1. Immune cells involved in inflammation -- 4.1.2. The foreign body response -- 4.2. Naturally occurring biomaterials with immune modulatory properties and their application in wound healing and reduct ... -- 4.3. Bioinstructive synthetic materials and their application in regenerative medicine -- 4.4. Developing ``immune-instructive�� biomaterials -- 4.5. Concluding remarks -- References -- Chapter 5: Electrospun tissue regeneration biomaterials for immunomodulation -- 5.1. Introduction -- 5.2. Acknowledging immunomodulation in tissue engineering -- 5.3. Well-studied areas -- 5.3.1. Monocytes and macrophages -- 5.3.2. Platelets -- 5.4. Areas gaining attention -- 5.4.1. Neutrophils -- 5.4.2. Mast cells -- 5.5. Areas needing attention -- 5.5.1. Dendritic cells -- 5.5.2. Eosinophils -- 5.5.3. Basophils -- 5.5.4. Natural killer cells -- 5.5.5. T cells -- 5.5.6. B cells -- 5.6. Future directions -- 5.7. Conclusion -- References -- Chapter 6: Biomaterials and immunomodulation for spinal cord repair -- 6.1. Spinal cord injury -- 6.1.1. Acute phase of SCI -- 6.1.2. Subacute phase of SCI -- 6.1.3. Chronic phase of SCI -- 6.1.4. Self-repair after SCI -- 6.1.5. Translational potential of animal models of SCI -- 6.2. Immune response after SCI -- 6.3. Immunomodulation after spinal cord injury -- 6.4. Biomaterials for spinal cord repair -- 6.5. Immunomodulatory biomaterials for spinal cord injury -- 6.5.1. Immunomodulation by surface chemistry -- 6.5.2. Immunomodulation by topography -- 6.5.3. Immunomodulation by delivering agents. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.5.3.1. Immunomodulation by providing biological ligands -- 6.5.3.2. Immunomodulation by delivering drugs -- 6.5.3.3. Immunomodulation by carrying cells -- 6.6. Natural immunomodulatory materials for spinal cord injury -- 6.7. Considerations and future directions -- 6.8. Conclusions and summary -- Acknowledgments -- References -- Chapter 7: Biomaterial strategies to treat autoimmunity and unwanted immune responses to drugs and transplanted tissu -- 7.1. Introduction -- 7.1.1. Burden of disease -- 7.1.2. Current treatment options and challenges -- 7.1.3. Immunological causes of aberrant immune responses -- 7.1.3.1. Immunological basis for autoimmune diseases -- 7.1.3.2. Immunological basis for transplant rejection, anti-drug antibodies, and allergies -- 7.1.4. Antigen-specific tolerance as a treatment goal -- 7.2. Scope -- 7.3. Biomaterials in development for autoimmunity and anti-drug antibodies -- 7.3.1. Lessons from trials of free peptide and free protein -- 7.3.1.1. Type 1 diabetes -- 7.3.1.2. Multiple sclerosis -- 7.3.2. Antigen delivery vehicles without additional regulatory cues -- 7.3.2.1. Antigen depots -- 7.3.2.2. Nanoparticles -- 7.3.2.3. Alternative nanoparticle vehicles -- 7.3.2.4. Targeting liver APCs -- 7.3.2.5. Targeting splenic APCs -- 7.3.3. Antigen delivery vehicles with additional regulatory cues -- 7.3.3.1. Small molecule immunomodulators -- 7.3.3.2. Cytokines -- 7.3.4. Peptide-MHC complexes -- 7.3.4.1. Soluble pMHC complexes -- 7.3.4.2. Multimeric pMHC complexes -- 7.3.4.3. Nanoparticle pMHC complexes -- 7.4. Biomaterials in development for transplant tolerance -- 7.4.1. Transplant ECDI-treated cells -- 7.4.2. PLGA scaffold with transplanted cells and additional immunomodulatory drugs -- 7.5. Future of the field -- 7.5.1. Challenges and future directions -- 7.5.1.1. Standardization of immunological goals and readouts. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.5.1.2. Further improvement in nanoparticle design -- 7.5.1.3. Manufacturability -- 7.5.2. Current or upcoming clinical trials -- References -- Chapter 8: Lipids as regulators of inflammation and tissue regeneration -- 8.1. Introduction -- 8.2. LC-MS based approaches to analyze lipids and their oxidation products -- 8.3. Free PUFA and their oxidation products as signals for immunomodulation and tissue regeneration -- 8.4. Oxidized phospholipids as modulators of the inflammatory response -- 8.5. Phospholipid signatures of EV -- 8.6. Hydrolysis of MBV derived oxygenated lipids and their possible role in inflammation and tissue regeneration -- References -- Chapter 9: Biomaterials modulation of the tumor immune environment for cancer immunotherapy -- 9.1. Introduction -- 9.2. Fundamentals of cancer immunology and immunotherapy -- 9.2.1. Cancer biology: Setting the stage -- 9.2.2. The role of immunity in cancer -- 9.3. Immunomodulatory biomaterials in cancer therapy -- 9.3.1. Cancer immunotherapy -- 9.3.2. Immunomodulatory biomaterials -- 9.3.3. Direct interactions between cancer and the biomaterial immune microenvironment -- 9.3.4. Biomaterial scaffold cancer vaccines -- 9.3.5. Biomaterial scaffolds for cell-based cancer immunotherapy -- 9.3.6. Immune tissue engineering -- 9.4. Summary -- References -- Chapter 10: Circumventing immune rejection and foreign body response to therapeutics of type 1 diabetes -- 10.1. Introduction -- 10.1.1. Type 1 diabetes (T1D) -- 10.1.2. Insulin and other injectable therapeutics -- 10.1.3. Biomaterials/devices -- 10.1.4. CGMs and insulin pumps -- 10.1.5. Cellular therapies -- 10.1.6. Protective immunity -- 10.2. Immune rejection for cells/grafts -- 10.2.1. General concepts for graft implementation -- 10.2.2. Transplant procedures -- 10.2.3. Human donor considerations -- 10.2.4. Alternative cell sources. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 10.2.4.1. Xenogeneic grafts -- 10.2.4.2. Allogeneic grafts -- 10.2.4.3. Syngeneic grafts -- 10.2.4.4. Autologous grafts -- 10.3. Biological hurdles to preventing graft rejection -- 10.4. Advances in eliminating rejection of non-encapsulated grafts -- 10.4.1. Edmonton protocol and anti-inflammatory strategies -- 10.4.2. Delivery of antigen/nucleotide-based drugs for rejection suppression -- 10.4.3. Engineering therapeutic cells to modulate immune response -- 10.4.4. Tolerogenic vaccines -- 10.4.5. Artificial antigen-presenting cells for inducing tolerance -- 10.5. Advances in preventing FBR to bulk encapsulation systems -- 10.5.1. Bioresorption vs. lack of biodegradability -- 10.5.2. Non-biodegradable hydrogels/alginate and stable immune isolation -- 10.5.3. Effects of altering physical architecture -- 10.5.3.1. Size and shape -- 10.5.3.2. Surface topography and selective porosity -- 10.5.4. Chemical modification of material devices -- 10.5.4.1. Identification of anti-fibrotic chemistries: Surface vs. bulk modified -- 10.5.4.2. Zwitterionic (and other polymer-based) biocompatibility coatings -- 10.5.5. Long-term controlled release systems for rejection prevention -- 10.6. Pre/clinical observations, and models for translation -- 10.6.1. Choosing the right test animal and transplant site -- 10.6.2. Blood flow and nutrient considerations for graft viability -- 10.7. Future prospects and perceived challenges/difficulties -- 10.7.1. Increasing burdens on healthcare -- 10.7.2. Population expansion and increasing age of the general human populace -- 10.7.3. Increase in emerging diseases -- 10.8. Summary/conclusion -- References -- Chapter 11: Machine learning and mechanistic computational modeling of inflammation as tools for designing immuno -- 11.1. Biomaterials, inflammation, and wound healing. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical materials. |
| 9 (RLIN) | 3868 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immune response |
| General subdivision | Regulation. |
| 9 (RLIN) | 69426 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biological response modifiers. |
| 9 (RLIN) | 69427 |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunologic Factors |
| Authority record control number or standard number | (DNLM)D007155 |
| 9 (RLIN) | 13564 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomat�eriaux. |
| Authority record control number or standard number | (CaQQLa)201-0025723 |
| 9 (RLIN) | 68433 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | R�eaction immunitaire |
| General subdivision | R�egulation. |
| Authority record control number or standard number | (CaQQLa)201-0018274 |
| 9 (RLIN) | 69428 |
| 650 #6 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immunomodulateurs. |
| Authority record control number or standard number | (CaQQLa)201-0000322 |
| 9 (RLIN) | 69429 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biological response modifiers. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00832312 |
| 9 (RLIN) | 69427 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biomedical materials. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00832586 |
| 9 (RLIN) | 3868 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Immune response |
| General subdivision | Regulation. |
| Source of heading or term | fast |
| Authority record control number or standard number | (OCoLC)fst00967872 |
| 9 (RLIN) | 69426 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Badylak, Stephen F., |
| Relator term | editor. |
| 9 (RLIN) | 69430 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Elisseeff, Jennifer H., |
| Relator term | editor. |
| 9 (RLIN) | 69431 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| International Standard Book Number | 0128214406 |
| -- | 9780128214404 |
| Record control number | (OCoLC)1220993192 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version : |
| Title | Immunomodulatory biomaterials. |
| Place, publisher, and date of publication | Oxford : Woodhead Publishing, [2021] |
| International Standard Book Number | 9780128214404 |
| Record control number | (OCoLC)1259525978 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Woodhead Publishing series in biomaterials. |
| 9 (RLIN) | 68481 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | ScienceDirect |
| Uniform Resource Identifier | <a href="https://www.sciencedirect.com/science/book/9780128214404">https://www.sciencedirect.com/science/book/9780128214404</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | eBooks |
No items available.